Application of In vitro transcytosis models to brain targeted biologics

• Published in: PloS one Vol. 18; no. 8; p. e0289970
• Main Authors: Deng, Kangwen, Lu, Yifeng, Finnema, Sjoerd J, Vangjeli, Kostika, Huang, Junwei, Huang, Lili, Goodearl, Andrew
• Format: Journal Article
• Language: English
• Published: San Francisco Public Library of Science 23.08.2023; Public Library of Science (PLoS)
• Subjects: Analysis; Animal models; Antibodies; Biological products; Biology and Life Sciences; Biopharmaceuticals; Blood; Blood-brain barrier; Brain; Cell culture; Central nervous system; Central nervous system agents; Correlation; Dosage and administration; Drug delivery systems; Drug development; Drugs; Electrical resistivity; Emission analysis; Endothelial cells; Endothelium; Epithelial cells; Epithelium; Immunoglobulin G; Ligands; Medicine and Health Sciences; Methods; Microvasculature; Modelling; Permeability; Physical Sciences; Positron emission; Positron emission tomography; Proteins; Radioactivity; Research and Analysis Methods; Scientific equipment and supplies industry; Screening; Software; Testing; Transferrin; Vehicles; Viral antibodies; United States
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0289970

The blood brain barrier (BBB) efficiently limits the penetration of biologics drugs from blood to brain. Establishment of an in vitro BBB model can facilitate screening of central nervous system (CNS) drug candidates and accelerate CNS drug development. Despite many established in vitro models, their application to biologics drug selection has been limited. Here, we report the evaluation of in vitro transcytosis of anti-human transferrin receptor (TfR) antibodies across human, cynomolgus and mouse species. We first evaluated human models including human cerebral microvascular endothelial cell line hCMEC/D3 and human colon epithelial cell line Caco-2 models. hCMEC/D3 model displayed low trans-epithelial electrical resistance (TEER), strong paracellular transport, and similar transcytosis of anti-TfR and control antibodies. In contrast, the Caco-2 model displayed high TEER value and low paracellular transport. Anti-hTfR antibodies demonstrated up to 70-fold better transcytosis compared to control IgG. Transcytosis of anti-hTfR.B1 antibody in Caco-2 model was dose-dependent and saturated at 3 [mu]g/mL. Enhanced transcytosis of anti-hTfR.B1 was also observed in a monkey brain endothelial cell based (MBT) model. Importantly, anti-hTfR.B1 showed relatively high brain radioactivity concentration in a non-human primate positron emission tomography study indicating that the in vitro transcytosis from both Caco-2 and MBT models aligns with in vivo brain exposure. Typically, brain exposure of CNS targeted biologics is evaluated in mice. However, antibodies, such as the anti-human TfR antibodies, do not cross-react with the mouse target. Therefore, validation of a mouse in vitro transcytosis model is needed to better understand the in vitro in vivo correlation. Here, we performed transcytosis of anti-mouse TfR antibodies in mouse brain endothelial cell-based models, bEnd3 and the murine intestinal epithelial cell line mIEC. There is a good correlation between in vitro transcytosis of anti-mTfR antibodies and bispecifics in mIEC model and their mouse brain uptake. These data strengthen our confidence in the predictive power of the in vitro transcytosis models. Both mouse and human in vitro models will serve as important screening assays for brain targeted biologics selection in CNS drug development.